Kornimate/medical-research-clean huggingface dataset:
effect of prazosin on neurophysiology and cognition in post-traumatic stress disorder (ptsd)

Conditions: Posttraumatic Stress Disorder

Summary: in this study, the investigators are looking at how ptsd affects things such as memory, attention, reaction to sounds, eye movements, and heart rate. the investigators are also studying whether a medication called prazosin has an effect on these things.

converging lines of evidence suggest that central nor adrenergic function is perturbed in ptsd. placebo-controlled trials demonstrate that the centrally acting alpha-1 antagonist prazosin is clinically effective for several core symptoms of ptsd in combat veterans. however, no detailed assessment of the impact of prazosin on human neurophysiology and cognition have been conducted. our hypotheses are based on studies that demonstrate (1) the importance of central adrenergic receptors in regulating fundamental neurophysiologic and cognitive functions, (2) the alteration of these functions in ptsd, and (3) the efficacy of prazosin in improving the clinical symptoms of ptsd. the primary objective of this study is to measure the subtle neurocognitive and neurophysiologic effects on prazosin in combat veterans with ptsd.

Eligibility criteria:
inclusion criteria: * exposure to one or more life-threatening war zone trauma events; * dsm-iv diagnosis of ptsd derived from the clinician-administered ptsd scale (caps), caps total score greater than or equal to 50; * caps recurrent distressing dreams item score greater than or equal to 5 (of a maximum score of 8), with a frequency rating greater than or equal to 2 (of 4); * stable dose of non-exclusionary medications and psychotherapeutic treatment for at least 4 weeks prior to randomization; * good general medical health; * female participants must agree to use a reliable form of birth control throughout study. exclusion criteria: * acute or unstable chronic medical illness; * diagnosis of current schizophrenia, schizoaffective disorder, psychotic disorder not otherwise specified, bipolar disorder, delirium, or cognitive disorder; * severe psychiatric instability or severe situational life crises; * substance dependence disorder currently or in past 3 months; * current cocaine or stimulant abuse or evidence of acute intoxication on alcohol or nonprescribed medication; * allergy or previous adverse reaction to prazosin or other alpha-1 adrenergic antagonists; * serious head injury with loss of consciousness of greater than 30 minutes; * current diagnosis of seizure disorder; * current use of prazosin or other alpha-1 adrenergic antagonists; * current use of atypical antipsychotic medication; * stimulants or alternative medications with stimulant properties (e.g. ephedra), certain exposure therapies must be completed at least 4 weeks before baseline; * certain medications (trazodone, erectile disfunction medications) are not allowed or are restricted during the study; * women must not be pregnant or nursing during the study.

Keywords: stress disorders, post-traumatic combat disorders prazosin cognition neurophysiology
accuracy of detection of dental caries from intraoral images using different artificiai intelligence models

Conditions: Dental Caries (Diagnosis); Artifical Intelligence; Intraoral Images

Summary: the goal of this observational study is to evaluate the diagnostic accuracy of different deep learning models in detecting dental caries from intra oral images taken by a professional intra oral camera in children. the main question it aims to answer is: what is the diagnostic accuracy of different deep learning models in detecting dental caries from intra oral images taken by a professional intra oral camera in children compared to the conventional clinical visual examination?


Eligibility criteria:
inclusion criteria: * child dentition having at least one decayed tooth. exclusion criteria: * child dentition with developmental enamel defects. * children with any systemic medical condition. * parent / child refuse to participate in the study. * uncooperative child.

Keywords: artificial intelligence dental caries diagnosis intraoral images
cd19 carvac t cells for patients with relapsed / refractory b cell malignancies

Conditions: B Cell Lymphoma; B Cell Leukemia

Summary: this is a phase i, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of cd19 carvac in patients with relapsed and/or refractory b cell malignancies.

cd19 carvac is a chimeric antigen receptor immunotherapy treatment designed to treat

Eligibility criteria:
inclusion criteria: 1. diagnosis based on the world health organization (who) 2008 2. patients have exhausted standard therapeutic options 3. systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks 4. female must be not pregnant during the study exclusion criteria: 1. prior solid organ transplantation 2. potentially curative therapy including chemotherapy or hematopoietic cell transplant 3. prior treatment with bcmaxcd3 or cs1xcd3 bispecific agents

Keywords: cd19 cd19 car t cell
assessment of sleep quality and mental health after using meditation

Conditions: Insomnia; Insomnia Chronic; Insomnia Disorder; Sleep Disorder; Anxiety Disorders; Stress Disorder; Depressive Disorder; Quality of Life; Complementary Therapy; Spirituality

Summary: this is a randomized controlled trial that intends to verify the effectiveness of the daily practice of meditation before going to sleep for the improvement of sleep, stress, mental health and quality of life of people with sleep problems.

participants selected for this clinical trial will be randomized into two groups: group 1 (intervention), with 87 participants undergoing 30 minutes of shabad kriya meditation before going to sleep, and group 2 (control), with 87 participants who will perform 30 minutes of relaxing reading before going to sleep. in addition, participants will complete the demographic data form; a sleep quality diary; and the scales: pittsburgh sleep quality index (psqi), perceived stress scale (pbs), five facets of mindfulness (ffmq), daily spiritual experiences (dses), functional assessment of chronic illness therapy - wellness scale spiritual (facit- 12), duke religiosity index (durel), quality of life - brief mode (whoqol-bref) and the depression, anxiety and stress scale (dass 21). the study is open to the general community, and those interested are screened through the "insomnia severity index" and questionnaires about health conditions. for conducting and guiding the intervention and completing the research instruments, online meetings will be held with the participants. the sleep quality diary will be completed for fourteen days before the start of the intervention (baseline). data collection will be carried out with online google forms questionnaires, sent through links in digital media, such as messages or emails, or made available in printed form. the main outcome measure will be sleep efficiency calculated using data from the sleep diary. data from participants with isi greater than or equal to 10 will be compared before and after the intervention. additionally, data analysis of participants with isi above or greater than 8 will be performed. at the end of the eighth week of the intervention (shabad kriya meditation or relaxing reading), as well as one month after the end of the intervention, and three months after the end of the intervention, the participants will again fill in the questionnaires described above, for statistical comparisons.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of insomnia (insomnia severity index between 8-28) exclusion criteria: * major medical or psychiatric problems * who has used sleeping pills or sleep-disrupting medications in the last 30 days prior to participating in the study * who will need to use sleeping pills or sleep-disrupting medications during the study
user performance evaluation for dario™ bgms

Conditions: Diabetes

Summary: the study aims to evaluate the accuracy of the blood glucose level results obtained from fingertip using the dario blood glucose monitoring system (bgms) compared to yellow springs instrument (ysi) as well as to evaluate the usability of the dario blood glucose monitoring system (bgms) by laypersons using only device labeling.

each subject enrolled in the study will be requested to follow the device instructions and perform his/her own finger-stick test using the dario blood glucose monitoring system (bgms). immediately after the subject tested him/herself a trained nurse/technician will collect another blood sample from the subject for testing by the yellow springs instrument (ysi). the subject will complete a usability questionnaire on his/her experience using the dario blood glucose monitoring system (bgms) and the nurse/technician will complete a questionnaire assessing the subject's performance. a venous blood sample for complete blood count (cbc) will be taken by the nurse/technician and sent for analysis.

Eligibility criteria:
inclusion criteria: 1. subject has type i or type ii diabetes 2. subject speaks and reads english proficiently 3. subjects owns and uses android and ios based smart mobile device for at least 1 year 4. subject is able and agrees to sign the informed consent form (minor subjects must be accompanied by a parent or legal guardian to provide consent for their participation in the study). exclusion criteria: 1. subject has medical training or works in the field of blood glucose monitoring system (bgms) 2. subject is critically ill 3. subject has an impairment that prevents him/her to follow the study procedures 4. subject has any condition that the principal investigator believes may interfere in the subject's participation in the study
interest of a post-operative ultrasound with systematic use of ultrasonic contrast in the follow-up of aortic endoprosthesis: prospective study at the university hospital of nice

Conditions: Aneurysm, Abdominal Aortic

Summary: this is a prospective study conducted on a population with an aortic endoprosthesis in the context of an abdominal aortic aneurysm. the study's objective is to standardize the ultrasound methodology in the monitoring of aortic endoprosthesis in immediate post-operative care by comparing the results with ct-scan (gold standard). to improve ultrasound methodology, the investigators propose to use the vesma protocol for ultrasound diameter measurement at four incidences. in addition, the use of ultrasonic contrast agents increases the accuracy of vascular structures, the quality of the ultrasound blood flow image and the duration of signal enhancement. this makes it possible to visualize small gauge vessels and those with slow flows. in this way, the investigators could improve the ultrasound technique for measuring aneurysm bag diameters and endoleak detection. moreover, the toxicity of iodinated contrast agents is the third cause of acute renal failure in hospitalized patients and is all the more frequent when the investigators increase injections. improving the quality of ultrasound investigations for the monitoring of aortic endoprosthesis would therefore allow us to reduce the number of ct-scan performed in this population and thus reduce irradiation and the injection of nephrotoxic products. thereby, the investigators would like to integrate the technique into the systematic follow-up of patients who have benefited from the placement of an aortic endoprosthesis by replacing the ct-scan.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * abdominal aortic aneurysm treated with aortic stent. * signature of informed consent. * person affiliated or beneficiary of a social security scheme exclusion criteria: * hypersensitivity to sulphur hexafluoride or to these excipients (macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol sodé, palmitic acid). * right-left shunt patient * patient with severe pulmonary hypertension (pulmonary blood pressure \> 90 mm hg), * patient with uncontrolled systemic hypertension * adult patients with respiratory distress syndrome. * dobutamine patient in patients with a pathology suggesting cardiac instability * hypercoagulation, recent thromboembolic accident * fenestrated aortic stent * pregnant or nursing woman. * severe heart failure. * person deprived of liberty by judicial or administrative decision. * person subject to legal protection.
analgesic effects of expectation and deep brain stimulation in patients with parkinson's disease

Conditions: Pain

Summary: the study investigates analgesic effects of expectations and deep brain stimulation on chronic and evoked pain in patients with parkinson's disease. the study includes patients with parkinson's disease that are exposed to pain stimuli through injection of hypertonic saline. during pain induction and chronic pain evaluation deep brain stimulation treatment is regulated. pain stimuli and regulation of deep brain stimulation are accompanied by verbal suggestions as to the analgesic effect of deep brain stimulation or no suggestions. during the test session patients evaluate their chronic and evoked pain and expectations. the study procedure is repeated on two separate test days to investigate pain during deep brain stimulation treatment with or without verbal suggestions. all participants will complete all study conditions with no suggestions and verbal suggestions, respectively.


Eligibility criteria:
inclusion criteria: * diagnosis of pd (confirmed by a neurologist) * bilateral implanted dbs in the stn during the study or for a minimum of 6 months exclusion criteria * other neurological or medical disorders (e.g. stroke, neuropathy, diabetes) or other disorders (e.g. musculoskeletal diseases) with expected influence on pain * dementia * untreated depression * patients unable to pause anti-parkinsonian medication * patients unable to cooperate * patients treated with painkillers except paracetamol and nsaid (except if pain and treatment is adequately stable as evaluated by a doctor)
phase 2a, 28-day investigational use study of arina-1 in non-cystic fibrosis bronchiectasis (ncfbe) with excess mucus and cough

Conditions: Non-cystic Fibrosis Bronchiectasis

Summary: this is a randomized, phase 2a, double-blind, placebo-controlled study to evaluate the safety and efficacy of arina-1 compared to placebo (isotonic saline, 0.9%) in participants with ncfbe. study participants will receive either study treatment or placebo twice daily for 28 days. efficacy endpoints will include quality of life, sputum rheological markers, and blood inflammatory markers. quality of life will be measured using the following tools: quality of life-bronchiectasis (qol-b) questionnaire, st. george's respiratory questionnaire (sgrq), chronic airways assessment test (caat), and a daily clinical global impression questionnaire.


Eligibility criteria:
inclusion criteria: * diagnosis of ncfbe confirmed by chest ct * 18-80 years old, inclusive at time of informed consent * bmi \>18 * percent predicted fev1 \> 40%, pre-bronchodilator * stable for 90 days with any airway clearance technique (act) method(s) * stable on standard of care (soc) therapy for 90 days (includes cycling antibiotics, such as inhaled tobramycin, and long-term macrolide therapy) and not likely, in the opinion of the investigator, to require any changes to therapy during the duration of study participation * fully vaccinated for covid-19 (second dose of a 2-shot regimen or single dose of 1-shot regimen completed \>14 days prior to the screening visit) * must be able to produce a sputum sample * if female and of childbearing potential, must be willing to use contraception for the duration of the study. exclusion criteria * positive urine pregnancy test for women of childbearing potential (wocbp) at screening and baseline visit * active exacerbation ≤28 days prior to the baseline visit * initiating or changing antibiotic, antiviral, or antifungal therapy ≤ 28 days prior to the baseline visit * changing or initiating any vitamin c, glutathione or n-acetyl-cysteine-containing therapy or multivitamin within 30 says prior to the screening visit. * positive covid-19 diagnostic test (pcr or antigen) within 90 days prior to the screening visit. * participated in other interventional drug or device studies within 30 days of the screening visit (note: observational studies are acceptable) * significant unstable comorbidities (in the opinion of the site investigator), such as heart failure, cardiovascular disease, diabetes, renal disease, liver disease * current tobacco or marijuana smoker (those with active smoking exposure \<180 days prior to the screening visit) (note: edibles are acceptable) * requiring the use of any supplemental oxygen * currently on cycled antibiotics (e.g., tobramycin) or have been on a cycled antibiotic regimen within 90 days prior to the screening visit. * current diagnosis of non-tuberculous mycobacteria (ntm) requiring antibiotic treatment. (participants who test positive for ntm but who are not currently on antibiotic therapy are eligible for screening)

Keywords: bronchiectasis
concentrations of amiodarone in fat tissue during chronic treatment

Conditions: Arrhythmia; Atrial Fibrillation; Atrial Flutter

Summary: the objective of this study is to determine if concentrations of amiodarone in fat tissue increases constantly over time during chronic treatment with this drug, and if blood concentrations reflect accurately the concentrations in fat tissue or not. this is because excessive concentrations of this drug in tissues can produce adverse effects.

amiodarone is very effective to treat cardiac arrhythmias but its use is limited by its toxicity, specially in chronic treatment. accumulation of the drug in tissues is very probably the cause of the majority of amiodarone delayed adverse effects. however, this has not been proved because obtaining tissue samples is usually difficult and aggressive. the investigators study, in patients following chronic treatment with amiodarone, if needle aspiration can provide samples of fat tissue useful to accurately determine amiodarone concentrations, how those concentrations in fat tissue correlate with cumulated dose, and how concentrations in fat tissue correlate with concentrations in blood, which is easier to obtain. the investigators expect this knowledge will help to understand how amiodarone develops its adverse effects and possibly lead to new ways of monitoring treatment with this drug, or to adapt doses in chronic administration.

Eligibility criteria:
inclusion criteria: * adult patients taking amiodarone for more than 3 months (any dose, any indication) exclusion criteria: * impossibility to perform needle aspiration of abdominal wall (local infection, skin disease) * coagulation disorders, inr \> 3.0 if warfarin treatment * patient unable to give informed consent

Keywords: anti-arrhythmia agents amiodarone, chronic treatment amiodarone, adverse effects biopsy, fine-needle, adipose tissue drug concentrations in tissues drug accumulation in tissues
clinical evaluation of composite restorations using two-steps universal adhesive in non-carious cervical lesion (nccl)

Conditions: Non-carious Cervical Lesion

Summary: the goal of this clinical study is to compare the clinical performance of a new 2-steps universal adhesive in patients with non-carious cervical lesions. the main question it aims to answer is: is there any difference in clinical performance of a new 2-steps universal adhesives bonded with different etching strategies. participants will have restorations using a new 2-steps universal adhesives in different etching strategies. * etch-and-rinse * selective enamel etching * self-etch


Eligibility criteria:
inclusion criteria: * available for follow-up visits * have at least 28 teeth/ 20 teeth under occlusion * have at least 3 non-carious cervical lesions without peri-apical lesion. the lesion is not nearly exposed pulp and no history of previous restoration. exclusion criteria: * rampant / uncontrolled caries * advanced untreated periodontal disease * \>2 cigarette packs/day * systemic or local disorders that could not undergo dental procedures * xerostomia * severe bruxism, clenching, tmd * pregnancy at the time of screening * known history of sensitivity to resin or related materials * fixed orthodontic appliance or planning to have orthodontic treatment within 3 years

Keywords: clinical trial universal adhesive etch-and-rinse selective enamel etching self-etch
laparoscopy in children: does it decrease the metabolic, endocrine and inflammatory stress response to surgery

Conditions: Gastro-Oesophageal Reflux

Summary: the aim of this trial was to characterise the intra and post operative metabolic, endocrine and inflammatory response to laparoscopic fundoplication in children. we are testing the hypothesis that laparoscopic fundoplication is associated with a lack of hypermetabolism and catabolism and blunting of the endocrine/inflammatory stress response


Eligibility criteria:
inclusion criteria: * infants and children with gastro-oesophageal reflux exclusion criteria: * septic shock, multi-organ dysfunction syndrome, cardiac, renal or congenital metabolic abnormalities
effects of orofacial myofunctional therapy on mental functioning and overall self-sufficiency in stroke patients

Conditions: Stroke

Summary: this project will explore the effects of orofacial myofunctional therapy on mental functioning and overall self-sufficiency in stroke patients. the population sample will be 70 divided randomly into two groups by concealed envelop method. then i will collect data from physiotherapy department wapda hospital complex, lahore. group a will be treated with routine physical therapy treatment that will include ems, infrared and intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes . group b will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes) .

this project will explore the effects of orofacial myofunctional therapy on mental functioning and overall self-sufficiency in stroke patients. the population sample will be 70 divided randomly into two groups by concealed envelop method. then i will collect data from physiotherapy department wapda hospital complex, lahore. group a will be treated with routine physical therapy treatment that will include ems, infrared and intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes . group b will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes) .according to the treatment protocol, the patients participated of the omt sessions, lasting 45 minutes each, with a weekly frequency during the first 30 days and every two weeks after this period, with no other additional therapeutic conducts5 (treatment duration = 120 days). a home exercise program was pre- scribed during each session. 10 personal activities: feeding, personal toileting, bathing, dressing and undressing, getting on and off a toilet, controlling bladder, controlling bowel, moving from wheelchair to bed and returning, walking on level surface (or propelling a wheelchair if unable to walk) and ascending and descending stairs.

Eligibility criteria:
inclusion criteria: * both gender * age (years) 40-70 * subacute stage of a strok exclusion criteria: - trauma (e.g., temporal bone fracture) * infection * herpes zoster (ramsay hunt syndrome) * borreliosis (lyme disease) * hsv reactivation * hiv * tumors (esp. parotid gland tumors) * pregnancy * diabetes mellitus * guillain-barré syndrome * sarcoidosis * amyloidosis * stroke